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ABSTRACT 
Lutein and zeaxanthin are the only carotenoids accumulated in the macula of the 
human retina and are known as the macular pigments (MP). These pigments account for the 
yellow color of the macula and appear to play an important role in protecting against age- 
related macular degeneration (AMD). The uptake of lutein and zeaxanthin in human eyes is 
remarkably specific. It is likely that specific transport or binding proteins are involved. Our 
objective is to determine whether transthyretin (TTR) is a transport protein in human plasma 
and could thus deliver lutein from the blood to the retina. In this study, we used a 
biosynthetic 13C-lutein tracer and gas chromatography-combustion interfaced-isotope ratio 
mass spectrometry (GCC-IRMS) to gain the requisite sensitivity to detect the minute 
amounts of lutein expected as a physiological ligand for human transthyretin. The 
biosynthetic 13C -labeled lutein tracer was purified from algae. Healthy women (n = 4) each 
ingested 1 mg of 13C-labeled lutein daily for 3 days and a blood sample was collected 24 
hours after the final dose. Plasma TTR was isolated by retinol-binding protein (RBP)- 
sepharose affinity chromatography and extracted with chloroform. The 13C/12C ratio in the 
TTR extract was measured by GCGIRMS. There was no 13Glutein enrichment in the pure 
TTR extract. This result indicated that lutein is not associated with TTR in human plasma 
after ingestion in physiological amounts. Some hydrophobic compounds with yellow color 
may bind to human TTR in the plasma. However, this association needs to be further proved 
by showing specificity. Our study provides a new approach for carotenoid-binding protein 
studies using a stable isotope tracer method combined with the high precision of GCC-IRMS. 
V 
The mechanism of selective transport, uptake, and accumulation of lutein in human macula 
remain to be determined. 
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CHAPTER 1. INTRODUCTION 
Age-related macular degeneration (AMD) 
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness 
among older people in Western counties. It occurs in 19.7% of the population over 65 in the 
U.S. (1). By the year 2025, an estimated 25.7 million people age 45 and older will have 
signs of AMD (2, 3). AMD is a progressive disease involving degeneration of the retinal 
pigment epithelium (RPE) and photoreceptor in the macular region. The macula is the small 
central part of retina. It is a slightly oval region of approximately 2-3 mm horizontal 
diameter that is centered on the fovea, where the visual axis meets the retina. The region has 
a yellow color which is only found in the primate retina and gives the macula a common 
name of yellow spot (macula lutea). Despite its small size, this region projects onto a large 
area of the visual cortex and has the highest density of cone photoreceptors which makes the 
macula functionally responsible for central vision and visual acuity. In AMD patients, 
changes of decreased density and/or uneven distribution of macular pigment (MP) (early 
AMD) with the degeneration of RPE cell and decline the number of photoreceptors 
(advanced AMD) are usually found (4, 5). These changes affect the function of the macula 
and result in loss of central vision and visual acuity. Activities essential for independent 
living, including reading, driving, writing, and recognizing familiar faces are impaired. The 
quality of life of elderly people is severely affected by AMD, so there is high motivation to 
prevent this disease. However, despite the significance of this disease, there is no available 
means to prevent it, and effective treatment is limited to only a small fraction of patients (5, 
6). The lack of effective interventions to prevent or treat AMD has made it one of the most 
frustrating diseases commonly encountered in ophthalmologic practice. 
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The pathogenesis of AMD is still not clearly understood. The major known risk factors 
for AMD: cigarette smoking, sunlight exposure, and low ocular melanin, probably related the 
pathogenesis to oxidative processes (1, 7, 8). Various insults that include normal metabolic 
processes within cells and possibly photochemical damage from ultraviolet and high-energy 
visible light (blue light) can initiate the oxidative process in the eye (9-11). The formation of 
free radicals and highly reactive singlet oxygen caused by these insults can lead to lipid 
peroxidation (7, 10). The high concentrations of polyunsaturated fatty acids in the 
photoreceptor outer-segment membranes and high exposure to blue light make the macula 
particularly vulnerable to these affects (11). These insults may cause damage, incompletely 
degraded molecules, impaired function of the retinal pigment epithelium, and, theoretically, 
could lead to degeneration involving the macula. 
Macular pigments 
Lutein and zeaxanthin are two dietary carotenoids which are found in normal human 
plasma and accumulated in high amount in the retina macular region known as the macular 
pigments (MP) (12, 13). These pigments account for the yellow color of the macula. 
Extensive work has shown that lutein and zeaxanthin are deposited specifically in the 
photoreceptor axon layer (Henle's fibers), the inner plexiform layer, and rod outer segment 
with zeaxanthin more concentrated in the foveal center and lutein spread more diffusely 
throughout the retina (13-16). The concentrations of the macular pigment rise remarkably to 
almost 1 mM in the central macula (17). This corresponds to more than 3-fold the 
concentration in normal serum and 500-fold the concentration in other tissues (17). This type 
of distribution implies that there must be a system to specifically take up, concentrate and 
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store exclusively lutein and zeaxanthin in the macula while excluding other carotenoids such 
as R-carotene and lycopene which are also abundant in the blood. 
These macular pigments appear to be especially important for normal macular function. 
The acuity hypothesis is the most long-standing although unproven hypothesis. It proposes 
that MP may decrease the adverse effects of the chromatic aberration in the ocular media by 
absorbing the poorly focused short-wavelength light, thereby increasing visual acuity (18- 
21). More recently, it is believed MP may protect against light-induced damage to the retina 
by filtering harmful bright short-wavelength light, or functioning as an antioxidant within the 
retina, or both (22-26). 
AMD and lutein 
Several large epidemiological studies suggested that dietary factors, particularly 
antioxidants, may have protective effects against AMD (9, 27,28). Seddon et al (1994) 
investigated the relationship between dietary carotenoids, vitamins A, C and E, and AMD in 
both patients and controls 55 to 80 years of age. Those in the highest category of lutein and 
zeaxanthin intake were 57% less likely to have advanced AMD (29). A protective role of 
lutein in preventing AMD is also suggested by research indicating that lower plasma lutein 
concentration and/or lower MP density are associated with higher ri sk of AMD. Macular 
pigment was depleted in monkeys fed diets deficient in lutein and zeaxanthin (30). 
Maintenance on such diets for up to 14 years resulted in retinal changes including loss of 
RPE cells and photoreceptor cells which are similar to the pathologic changes of AMD. 
Human studies have also investigated the relation of plasma and macular lutein levels with 
the ri sk of AMD. The Eye Disease Case Control Study (EDCCS) Group compared the 
fasting serum samples of 615 control and 412 patients recently diagnosed with AMD. Those 
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with lutein/zeaxanthin concentration > 0.67 µmol/L were 70%less likely to have AMD than 
those with concentration < 0.25 µmoUL (9). An autopsy study found that macula from 
patients with a history of AMD had lower concentrations of MP relative to control eyes from 
patients without a known history of AMD (31). Hammond et al. in 1998 showed a positive 
relationship between MP density and visual sensitivity (32). Bone et al (2001) compared the 
MP concentrations of retinas from 56 donors with AMD to those without AMD. The results 
suggested that individuals with low lutein and zeaxanthin in their retinas are at greater risk of 
acquiring AMD (33). 
A large body of evidence indicates that both plasma concentration and MP density can be 
modified by diet. Nutritional studies have demonstrated that increased consumption of foods 
or supplements rich in lutein and zeaxanthin elevated serum levels of these carotenoids and 
in many cases resulted in increased serum lutein concentration and MP density (34-38). In 
addition, several recent studies reported improvements of visual function (e.g., higher 
contrast sensitivity, higher glare sensitivity, improved color perception, and improved visual 
acuity) in some AMD patients with lutein supplementation (39- 41). In contrast, several 
other studies found no consistent association between lutein and AMD. Mares-Perlman et al 
reported that there is no significant association between lutein and zeaxanthin intake and 
AMD in a retrospective study, The Beaver Dam Eye Study (42). Mares-Perlman et al. 
(1995) also found no significant differences in the mean non-fasting serum lutein 
concentrations in AMD cases and controls (43). However, the range of serum 
concentrations of lutein and zeaxanthin in this study was not as great as that observed in the 
Eye Disease Case Control Study (EDCCS). Similar results were also observed by Vanden 
Langenberg (44) and Sanders (45). 
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Lutein and its metabolism 
Lutein and zeaxanthin are the only carotenoids accumulated in the macula of the human 
retina (12, 13). It is also well established that peripheral retina and lens are enriched in these 
carotenoids (14, 46, 47). In addition, Bernstein et al (1999) reported that quantifiable levels 
of lutein, zeaxanthin, their geometrical (E/Z) isomers, and their metabolites were found in 
other ocular tissues (iris, ciliary body) (48). The uptake of lutein and zeaxanthin in human 
eyes is remarkably specific because many other prominent serum carotenoids such as a- 
carotene, (3-carotene, (3-cryptoxanthin, and lycopene have not been found in eye tissues. 
Lutein and zeaxanthin are structural isomers (Figure 1). They are more polar than many 
other carotenoids and have hydroxyl groups on the cyclic end rings. The hydroxyl groups 
may allow them to incorporate into the cell membrane in an orientation that stabilizes the 
membrane. The only structural distinction between lutein and zeaxanthin is the placement of 
one double bond. The allylic hydroxyl of lutein is much more easily oxidized than the 
secondary hydroxyl groups present in zeaxanthin (49, 50). The normal Western diet contains 
1-2 mg/day of lutein (51). Lutein is found in the diet in larger quantities than zeaxanthin. It 
has been estimated that the ratio of lutein to zeaxanthin in the diet ranges from about 4:1 to 
7:1 (52, 53). In human serum, like the diet, lutein dominates over zeaxanthin. The ratio of 
lutein to zeaxanthin ranges from 2.7 to 4.5:1 and depends upon diet and individual 
characteristics such as genetics and lifestyle (54-57). Therefore lutein is thought to be the 
more essential carotenoid. 
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Figure 1. Chemical structures of lutein and zeaxanthin. 
Despite the putative importance of lutein in human health, many aspects of the absorption 
and metabolism of lutein and other carotenoids are not well understood. The biochemical 
mechanisms that mediate the selective uptake, concentration, and stabilization of the macular 
pigment are unknown. Why does the retina accumulate lutein and zeaxanthin to the 
exclusion of other carotenoids, such as ~3-carotene and lycopene, which are abundant in the 
blood? Why have some epidemiological and nutritional studies failed to find a relation 
between serum concentrations of lutein and zeaxanthin and risk of AMD? To answer these 
questions, more detailed information on lutein metabolism is needed. To our understanding, 
when a tissue exhibits highly selective uptake of a chemical compound, it is likely that 
specific transport and/or binding proteins are involved. Hence it is reasonable to hypothesize 
that there is alutein-binding protein family present in human plasma and retina to transfer 
lutein from the diet via blood to the retina and mediate the uptake and accumulation of the 
high concentrations of lutein and zeaxanthin in human eye. Any interindividual differences 
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in this delivery system would help to explain the inconsistent results from previous studies. 
More importantly, abnormalities in this hypothetical delivery system would have profound 
effects on macular function and could be involved in the pathogenesis of AMD. 
Carotenoid-binding proteins in plants and invertebrates have been purified and 
extensively studied. The plant and algal proteins are usually involved in photosynthesis or 
photoprotection (58, 59). a-Crustacyanin is a 350 kDa astaxanthin-binding protein 
responsible for the color of lobster shells (60). A lutein-binding protein that maybe involved 
in the specific uptake of dietary lutein in the midgut of the silkworm has been purified and 
partially characterized by Jouni and Wells (61). This protein has a molecular weight of 35 
kDa but the amino acid sequence has not been defined. The lutein—protein complex is water 
soluble and more stable than lutein or protein alone. Preliminary data suggests that lutein 
binds to the hydrophobic sites of the protein. 
Much less is known about carotenoid-binding proteins in vertebrates. A 67 kDa soluble 
(3-carotene-bind protein was isolated from ferret liver by Rao et al. (62), but the sequence was 
not reported. This protein prefers binding to carotene over xanthophylls. Bernstein et al. 
(63) reported that retinal tubulin, a 55 kDa water soluble protein abundant in the 
photoreceptor axon layer, binds macular carotenoids in bovine. In the same study, soluble 
extracts of human macula were also partially purified. HPLC analysis showed that 
endogenous lutein and zeaxanthin copurified with tubulin. However, binding affinity studies 
using bovine brain tubulin indicated that many carotenoids, including (3-carotene, can bind to 
tubulin. Hence it is unlikely that tubulin is the mediator protein accounting for the specific 
uptake of macular pigments unless cone tubulin has a particularly high affinity and 
specificity for lutein and zeaxanthin. Recently, two human retinal membrane-associated 
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proteins, xanthophyll-binding proteins (XBP), which contain two major proteins bands at 25 
kDa and 55 kDa have been partially purified and show strong and specific binding affinity 
for macular lutein and zeaxanthin with little or no affinity for other carotenoids (64). 
Comparison of XBP to other potential mammalian carotenoids-binding proteins (tubulin, 
lactoglobulin and serum lipoproteins) using the peak A460/A280 ratios showed that only XBP 
exhibited a high specificity for lutein and zeaxanthin. It is likely that membrane associated 
XBP plays a role in mediating the uptake of lutein and zeaxanthin in human retina. However, 
further purification and characterization need to be performed in order to provide stronger 
evidence. In human plasma, low-density lipoproteins (LDL) and high-density lipoproteins 
(HDL) are the major carriers of carotenoids (65). Lutein and zeaxanthin are evenly 
distributed between HDL and LDL while (3-carotene and lycopene are preferentially carried 
by LDL (65-67). However, HDL and LDL do not specifically bind lutein and/or zeaxanthin, 
and there is no HDL or LDL receptor founded in the human retina. Thus these two 
lipoproteins could not be responsible for the selective delivery of lutein and zeaxanthin from 
the blood to the retina. Pettersson et al. (68) reported that lutein is associated with 
transthyretin (TTR) in chicken plasma. This was the first report that lutein is associated with 
TTR. The finding of specific binding of lutein to chicken TTR may offer a functional role 
for TTR in the retina. 
Transthyretin (TTR) 
Transthyretin (TTR) is a multifunctional protein found in the plasma in many species. 
The structure of TTR is well conserved throughout evolution (69). Human TTR (previously 
called prealbumin) occurs in human plasma as a tetramer composed of apparently identical 
subunits each of 14 kDa molecular weight (70, 71). The two well-established functions of 
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human TTR are transport of thyroxine (72) and transport of retinol (vitamin A) via the 
retinol-RBP-TTR complex (73). But other functions have been considered. In plasma, 
retinol is bound to retinol-binding protein (RBP; MW 21,000) which is associated with TTR 
in 1:1 molar ratio. This transport complex serves to solubilize the hydrophobic retinol 
molecule and stabilize the retinol-RBP and protect RBP during glomerular filtration (74, 75). 
RBP receptors are present on the basal and lateral membranes of the RPE cells (76). Retinol 
is transported to the retinal pigment epithelium (RPE) cell by the RBP-TTR complex and 
may enter the RPE cell without RBP (77). In the RPE cell, retinol is esterified and then 
carried to the photoreceptors by an interphotoreceptor retinal-binding protein (IRBP) (78). 
Retinol is transported by IRBP between RPE and photoreceptors as part of the visual cycle 
that regenerates the visual pigments after they have absorbed light and triggered electrical 
signals. 
TTR is primarily synthesized in the liver (79). But the synthesis of TTR is also been 
found in several extrahepatic sites such as central nervous system and eye. Several studies 
reported that TTR is synthesized and secreted by the choroids plexus epithelium (80-82) but 
the precise role of TTR within the central nervous system has not yet been determined. In 
the eye, TTR has widespread distribution in a variety of ocular cells such as RPE, ciliary 
epithelium, iris epithelium, corneal endothelium, and lens capsule (83). However mRNAs of 
TTR are only found in the retinal pigment epithelium (RPE) cell (84). Then RBP was 
reported to be synthesized in the RPE cell by Herbert et aL (85). Ong et al. (1995) confirmed 
that both TTR and RBP can be synthesized and secreted by cultured RPE cells, and it is 
found that the secretion ratio of TTR to RBP was as high as 50:1 (86). The function of 
ocular TTR and RBP are unknown. It was proposed that they may play a role in the 
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intraocular processing of retinol (83). It is also likely these proteins involved in the delivery 
of all-trans-retinol to amacrine and Muller cells as a precursor for retinoic acid since these 
cells are know to have cellular retinoic acid binding protein (87). TTR might be serving 
some function in the retina which is unrelated to its ability to form a complex with RBP 
given its extremely high expression in the RPE. Notably, in Pettersson's study (68), 
association of lutein is a specific finding for TTR, as no lutein could be identified in similar 
extracts of chicken RBP. Also, the binding seems to be specific for lutein, as none of the 
other common carotenoids were found to be associated with TTR. These results provide a 
potential explanation for the selective accumulation of lutein in the macula if lutein is 
associated with TTR and transported from the bloodstream to the RPE via RBP-TTR 
complex or TTR alone. Ernstrom (88) also identifiied a yellow pigment associated with 
human TTR but it was not lutein. Their results showed that the major yellow component 
extracted from human TTR had properties similar to a pterin derivative. However, there are 
two major limitations in Ernstrom's human study. First, chickens are fed rations 
supplemented with lutein as a source of broiler and yolk pigmentation (89). This results in 
serum lutein concentrations in chickens that are 20-fold higher than in humans. The human 
retina contains only 5-40 ng lutein concentrated within the macula (24). Hence conventional 
HPLC analysis may not detect the low amount of lutein expected to be bound to TTR in 
unsupplemented subjects. In Ernstrom's study, the investigators used acidic methanol in the 
extraction of the yellow component from the TTR fraction. The, acidic methanol is not a 
good solvent for carotenoid extraction. The acid may cause lutein degradation. We 
hypothesized that use of a milder extraction protocol and more sensitive instrument would 
overcome these limitations in Pettersson's study. 
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Gas chromatography combustion-isotope ratio mass spectrometry (GCC-IRMS) and its 
application in carotenoid research 
High-precision gas isotope ratio mass spectrometry (IIZMS) is the classical technique for 
determination of isotope ratio due to natural processes for C, H, N, O, and S (90). In the 
1900s, gas chromatography (GC) was interfaced to IRMS by a microcombustion furnace 
(91). This new technology, GCC-IRMS, enabled high-precision stable carbon isotope 
analysis of individual, volatile organic compounds in chemically complex samples separated 
by GC. With its character of high sensitivity and capability for stable isotope analysis, GCC- 
IRMS enables a unique tracer approach for carotenoid research (91). Since carotenoids are 
mainly ingested in the diet and no animal model can be used to replace the human, a stable 
isotope tracer method is often essential for study of carotenoid metabolism in humans. With 
GCC-IRMS, we are able to administer a physiological dose of carotenoid and avoid the 
health risks of radioactive material. 
Several studies have used GCC-IRMS to investigate the metabolism of ~3-carotene and 
lutein in humans (92-95). We showed that application of this technique to study of lutein 
metabolism requires the conversion of lutein to athermally-stable perhydro analog (94, 95). 
The catalytic hydrogenation of lutein and acid-catalyzed removal of the hydroxyl groups 
produces the major product perhydro-(3-carotene (m/z 558.6) and secondary products (95). 
The secondary products have mass spectra at m/z 574.4 and m/z 572.6 that are consistent 
with saturated and monounsaturated forms of anhydrolutein, a product which most likely 
results from the favored acid-catalyzed dehydration of the allylic hydroxyl group of lutein 
(96). 
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In this study, we will use a biosynthetic 13C-lutein tracer and gas chromatography-
combustion interfaced-isotope ratio mass spectrometry (GCC-IRMS) to gain the requisite 
sensitivity to detect the minute amounts of lutein expected as a physiological ligand for 
human transthyretin. Our overall objective is to achieve a detailed understanding of the role 
of lutein in ocular health. The specific aim for this study is to determine whether lutein is 
associated with TTR in human plasma and the extent to which lutein is bound to TTR. We 
expect that our study will help to understand the mechanism responsible for the selective 
uptake and concentration of lutein in the macula. This mechanism could be used to increase 
the .density of the macular pigment and, potentially, to prevent the progressive blindness 
caused by age-related macular degeneration. 
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MATERIALS AND METHODS 
1. Human metabolic methods: Study protocols were approved by the Human Subjects 
Review Committee of Iowa State University. 
1.1 Subjects 
Healthy female nonsmokers (n = 4) 19 to 3 8 years of age were selected based on 
interview, anthropometric assessment (height and weight, body mass index), and normal 
complete blood count, including hemoglobin and hemocrit. Subjects had blood hemoglobin 
concentration greater than 125 g/L as measured at the Iowa State University Student Health 
Center within a 7-day period preceding blood donation for the study. Criteria for exclusion 
included current or recent cigarette smoking; frequent alcohol consumption (> 1 drink/day); 
recent use of medications that may affect lipid absorption or transport (including antibiotics); 
use of multivitamin, lutein, beta-carotene, or other carotenoic~ supplements during the 
previous 3 months; aversion to phlebotomy or the sight of blood; whole blood donation 
within 8 weeks preceding scheduled blood donation for the study; history of anemia or 
excessive bleeding; history of macular degeneration or other eye diseases, chronic diseases, 
lipid malabsorption or gastrointestinal disorders, lactose intolerance, abnormal thyroid status, 
photosensitivity; atypical food habits (e. g., severe reducing diet, anorexic diet, 
hypercarotenemic diet, vegetarian diet); atypical body weight (i.e., less than 120 pounds or 
greater than 130% of the mean weight for height and age); current or planned pregnancy, 
menstrual cycle irregularities or abnormalities (including heavy menstrual periods), use of 
oral contraceptives. 
1.2 Study diet 
Subjects were instructed to avoid dietary supplements, fruits, and vegetables with a 
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high content of lutein fora 3-week period preceding the dosing protocol. The intent was to 
deplete serum transthyretin of lutein originating from the diet in order to maximize saturation 
of the transthyretin with lutein originating from the test doses. 
1.3 13C-Lutein dosing protocol 
Subjects ingested an emulsion prepared with banana (30 g), fat-free milk (70 mL), and 
high oleic sunflower oil (28 g, purchased from Abitec Corporation, Janesville, WI, USA) 
which contained 1.0 mg of 13C -labeled lutein (95). Subjects ingested the emulsion each day 
under observation over a 3-day period in the Human Metabolic Unit in the Center for 
Designing Food to Improve Nutrition at Iowa State University. The 1.0 mg daily dose of 
lutein simulates the average daily intake of lutein in the U.S. population (51). 
1.4 Blood collection 
Each subject donated S 00 mL of blood for isolation of transthyretin 24 h after 
ingestion of the third and final dose of 13C -labeled lutein. Blood was collected in the Human 
Metabolic Unit of the Center for Designing Food to Improve Nutrition by an experienced 
registered nurse employed as a phlebotomist at the local blood bank. A clinical assessment 
including blood pressure, pulse, and body temperature was performed for each subject 
immediately before and after the blood donation. Exclusion criteria included systolic blood 
pressure less than 100 or higher than 180 mm Hg, pulse less than 50 or higher than 100 per 
minute, and body temperature higher than 37.2° C. Subjects donated 500 mL of blood while 
supine. Standard phlebotomy technique for whole blood donation was used. A 600 mL 
Baxter Fenwal Transfer Pack Container (Baxter Heather Corporation, Deerfield, IL, USA) 
and a Terumo Surflo Winged Infusion Set (Terumo, Corporation, Tokyo, Japan) were used to 
collect the blood during donation. Each subject was required to remain supine for a 
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minimum of 10 min and was then shifted to a seated position for at least 5 min. The subjects 
were then instructed to drink at least 8 ounces of apple juice to replace lost blood volume. 
Subjects were permitted to leave the Human Metabolic Unit 10 minutes later if 
asymptomatic. Blood was taken to the Blood Bank of Mary Greeley Hospital (Ames, IA) to 
separate the plasma. The individual plasma samples were stored at — 70° C until used for 
isolation of transthyretin. 
2. Tracer (13C-lutein) preparation 
Purified 13C-labeled lutein is not commercially available. Crude lipid extract from algae 
grown under an environment of 13C labeled CO2 was purchased from Martek Bioscience Inc 
(Columbia, MD, USA). In the algae, all components were uniformly-labeled with 13C. The 
carotenoid composition of the crude lipid extract was determined by high performance liquid 
chromatography (HPLC) to be 65% lutein, 30% ~3-.carotene, and 5%unidentified carotenoids. 
In order to purify lutein, 200 mg of crude algal extract were transferred to a 50-mL screw-
capped glass test tube. 25 mL of acetone (HPLC grade) were added and mixed, followed by 
vortexing for 2 min. The mixture was centrifuged (2000 rpm X 10 min). The upper acetone 
layer was carefully removed. This extraction process was repeated until the yellow color of 
the paste/acetone mixture almost disappeared. The acetone extracts were combined and 
dried under argon to a volume of 50 mL and then transferred to a separatory funnel. 80 mL 
of hexane was added to the funnel. Then 30 mL of distilled water was carefully added to the 
funnel until the acetone and hexane layer were clearly separated. The acetone and water 
layer was discarded. The upper hexane layer was washed with 30 mL of water in the 
separatory funnel. After discarding the water, 80 mL of methanol and water (95:5 by vol) 
were added to the funnel to partition the lutein from the hexane. Without shaking, the lower 
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methanol and water layer was collected and transferred to another separatory funnel. An 
equal volume of ethyl ether was added to the funnel. Then water was added until two layers 
formed. The lower methanol and water mixture were discarded. The upper ethyl ether layer 
was then divided equally among four 50-mL screw-capped glass test tubes. Water (5 mL) 
was added to each tube, mixed, and centrifuged at 2000 rpm for 30 min. The ethyl ether 
fractions was combined and dried under vacuum. The dried residue was then dissolved with 
4 mL of hexane. The mixture was vortexed and transferred to a microfiltration apparatus. 
Hexane (100 mL) was added to the funnel to wash the residue continuously during the 
filtration. After drying, the red product on the filter paper was transferred to a 5-mL screw- 
capped glass vial. Warm methanol (2 mL) was added to redissolve the red product. The vial 
was heated until the solution was clear. The methanol solution was allowed to cool to room 
temperature. Hexane (2 mL) was then added to the vial drop wise and with shaking. The 
vial was then filled with argon and stored at — 20° C overnight for crystallization. The 
methanol solution containing the red lutein crystals was transferred to the microfiltration 
apparatus. The cumulative product of 5 to 7 days was combined to avoid losses resulting 
from use of a small quantity during the operation. The lutein crystals were washed with 50 
mL of hexane. The product was left in the dark in a fume hood for 8 h to allow the solvent to 
evaporate. The final product was stored in a small glass vial under argon in the dark at -80° 
C. By using this protocol, approximatelyl mg of lutein was purified from 200 mg of crude 
algal extract. 
3. Purify TTR and RBP from outdated human plasma (All operations were carried out in 
a cold room at 4° C. The isolation method was modified based on a protocol generously 
provided by Dr. David Ong, Vanderbilt University.) 
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3.1 Plasma sample preparation 
Outdated human plasma was generously donated by the Blood Bank of Mary Greeley 
Hospital (Ames, IA). One liter of plasma was filtered though a 1/4-in bed of celite to remove 
lipid. Then the plasma was divided among 10 segments of dialysis membrane tubing 
(Spectrum Medical, Inc, Los Angeles, CA, USA) with MWCO of 6000 to 8000 and dialyzed 
against 5 L of 0.05 M phosphate buffer pH 7.4 containing 0.05 M NaCI. The dialysis was 
extended to 16 h and the buffer was changed 4 times during this period (1St hour, 2"d hour, 3ra 
hour, and 15th hour). 
3.2 Saturate the RBP with all-trans-retinol 
All-trans-retinol was purchased from Sigma Chemical (St. Louis, MO, USA). A stock 
solution of 1 mg retinol/mL in ethanol was prepared according to the instructions of the 
supplier. The concentration of retinol solution was determined using a molar extinction 
coef~ cient of 46000 at 3 3 0 nm. The retinol stock solution was stored at —20° C under 
nitrogen in a brown glass vial. Immediately before use, the retinol stock solution was diluted 
by dimethylsulfoxide (DMSO) to about 5 X 10 .4 M. The freshly made DMSO solution was 
added to the dialyzed plasma using a glass pipette. An equimolar amount of retinol to 
retinol-binding protein was used. The mixture was incubated for 30 min for at room 
temperature in the dark. The plasma was then centrifuged at 10000 X g for 30 min to remove 
any precipitate. 
3.3 Ion exchange chromatography (DEAE column) 
The DEAE column (2.5 X 22 cm) was packed in our lab with DE 52 (Whatman 
International Ltd, Maidstone, Kent, England). The clear plasma supernatant was applied to 
the DEAE column which had been equilibrated with 10 bed volumes of dialysis buffer. The 
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eluate was monitored with an ISCO UA-6 absorbance detector (ISCO, Inc, Lincoin, NE, 
USA) set at 280 nm. After the plasma was pumped onto the column, it was washed with 
0.05 M phosphate buffer pH 7.4 containing 0.05 M NaCI until there was no absorbance at 
280 nm. Immediately after the wash, elution was carried out with a linear gradient of NaCI 
from 0.05 M to 0.5 M in 0.05 M phosphate buffer, pH 7.4. Fractions of 5 mL were collected 
by using a CF-1 Fraction Collector (Spectrum Chromatography, Huston, TX, USA) at a flow 
rate of 70 mL/h. A total of 100 tubes were collected and tested for absorbance at 280 nm, 
330 nm, and 400 nm by using a Hewlett Packard-8452A Diode Array Spectrophotometer 
(Boehringer Mannheim, Indianapolis, IN, USA). Fluorescence (exc 3 3 5 nm, ext 460 nm) 
was also measured for all tubes using a Waters 474 Scanning Fluorescence Detector (Waters 
Corporation, Milford, MA, USA). Fractions with both fluorescence and UV absorbance 
were pooled and saved. This combined fraction contained the retinol-binding protein (RBP)- 
transthyretin (TTR) complex. 
3.4 Ammonium sulfate precipitation 
The fraction containing the pooled RBP-TTR complex was reduced in volume to 100 mL 
by using an Amicon Ultraflltration Cell (Amicon, Inc, Beverly, MA, USA) with a YM-3 
filter (Millipore Corporation, Bedford, MA, USA) under nitrogen pressure. The sample was 
then precipitated with 1.5 M ammonium sulfate and 2 M citric acid was used to adjust the pH 
to 6.0. The solution was allowed to stand overnight. It was centrifuged at 10000 X g for 10 
min and the supernatant was saved. 
3.5 Hydrophobic interaction chromatography (phenyl-sepharose column) 
The phenyl-sepharose column (2.5 X 33 cm) was packed in our lab with phenyl-
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sepharose CL-4B purchased from Sigma. The clear supernatant obtained from the 
ammonium sulfate precipitation was applied to the phenyl-sepharose column which had been 
equilibrated with 10 bed volumes of 0.05 M citrate buffer pH 6.0 containing 1.5 M 
ammonium sulfate. Fractions of 10 mL were collected at a flow rate of 120 mL/h. 
Immediately after loading the protein sample, elution was started with a linear gradient from 
the starting buffer to 0.03 M phosphate buffer, pH 7.0 (1500 mL). Fractions were tested for 
absorbance at 280 nm, 330 nm, and 400 nm as described above. Two protein fractions were 
detected. The TTR fraction comprised a large peak between tubes 50 and 120. The RBP 
fraction was eluted before tube 150. These fractions distributed among multiple collection 
tubes were pooled in 3 to 4 tubes for further use. 
3.6 Ion exchange chromatography (2"d DEAE column: 2.5 X 30 cm) 
The fraction (about 150 mL) containing TTR was dialyzed overnight against 0.05 M 
Tris-acetate buffer, pH 8.3. The buffer was changed 4 times. The dialyzed protein sample 
was then applied to a 2"a DEAE column which had been equilibrated with the dialysis buffer. 
Fractions of 5 mL were collected at a flow rate of 60 mL/h. Fractions were tested for protein 
absorbance as above. The major peak (peak 2) which contained TTR was pooled and 
concentrated using the YM3 membrane in the Amicon Ultrafiltration Cell. The concentrated 
sample was stored in several tubes at — 80 °C until used for packing the affinity column. 
3.7 Preparation of the TTR-sepharose affinity column 
(1) Couple TTR with the affinity media 
Human TTR was isolated in our lab from outdated plasma as described above. The 
protein was concentrated and dialyzed using a Micro ProDiCon CE membrane (Spectrum, 
Houston, TX, USA) in a Micro-ConFilt Vacuum Dialysis Unit (Bio-Molecular Dynamics, 
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Beaverton, Oregon, USA) generously loaned by Dr. Barbara Wiggert, Laboratory of Retinal 
Cell and Molecular Biology, National Eye Institute, Bethesda, MD, USA. 0.1 M NaHCO3 
buffer containing 0.5 M NaCI, pH 8.3 was used as dialysis buffer. CNBr-activated 
Sepharose 4B was obtained from Amersham Pharmacia Biotech (Piscataway, New Jersey, 
USA). A desired amount of freeze-dried powder of CNBr-activated Sepharose 4B was 
weighed (1 g freeze-dried powder gives 4-5 mL drained gel). The powder was transferred to 
a screw-capped glass centrifuge tube and suspended in 1 mM HCl for at least 30 min. The 
resin and HCl mixture were then centrifuged at low speed (3000 rpm) for 5 min. The 
supernatant was removed by pasteur pipette and additional 1 mM HCl was added followed 
by shaking. The mixture was then centrifuged again as above. The wash with HCl was 
repeated 2 more times. A total of 200 mL of 1 mM HCl was needed to swell and wash 1 g 
powder. The HCl supernatant was discarded and 10 volumes of deionized water were added 
to the tube. The sample was then mixed and centrifuged at 3000 rpm for 5 min. The 
aqueous supernatant was removed and about 5 bed volumes of coupling buffer (0.1 M 
NaHCO3 containing 0.5 M NaCI, pH 8.3) were added to the resin. The mixture was 
centrifuged to remove the supernatant. Protein solution (protein in coupling buffer) was 
added to the gel immediately (about 5-10 mg protein per mL of gel). Protein and gel were 
mixed in a glass tube by rotating overnight at 4 °C. The excess ligand was washed away 
with 5 bed volumes of coupling buffer. The unreacted groups were then blocked by adding 1 
M ethanolamine, pH 8. The block reaction was carved out at 4 °C for at least 16 h. The 
blocking solution was then washed extensively with a cycle of 10 bed volumes of cold 
deionized water followed with 10 bed volumes of coupling buffer 5 times. The washings 
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were collected and concentrated. The binding ability of the TTR and ligand was 
approximately 96% during the coupling procedure. 
(2) Pack the TTR-sepharose affinity column 
The slurry was degassed under vacuum before packing and then pulled into an empty 
glass column purchased from Bio-Rad (Bio-Red Laboratories, Hercules, CA, USA). The 
column was allowed to settle followed by equilibration with 0.01 M PBS buffer containing 
0.5 M NaCI, pH 7.4 at a flow rate of 2.5 mL/min. The column was stored at 4 °C with 2 naM 
sodium azide added to the buffer. In our study, 3 5 mg of TTR was coupled with the CNBr-
activated sepharose 4B affinity media to pack a 5 mL (1.5 X 3.0 cm) TTR-sepharose affinity 
column. 
3.8 Purify the retinol-binding protein using the TTR-sepharose affinity column 
RBP sample was partially purified using the phenyl-sepharose column described above. 
The sample was dialyzed using aSlide-A-Lyzer Dialysis Cassette (Pierce, Rockford, IL, 
USA) with 0.01 M PBS buffer containing 0.5 M NaCI, pH 7.4. The dialyzed sample was 
applied to our TTR-sepharose affinity column (1.5 X 3.0 cm) which had been equilibrated 
with the dialysis buffer. Fractions of 2 mL were collected and the flow rate was adjusted to 
1.0 mL/min. After the sample was pumped onto the column followed by 1 mL of starting 
buffer, the flow was stopped for 20 min to ensure the binding of RBP to the gel matrix. The 
column was then washed with 3 bed volumes of starting buffer followed with 3 bed volumes 
of 0.01 M PBS (no NaCI). The RBP fraction was eluted with deionized water. The pure 
RBP from several runs was pooled and concentrated by the Vacuum Dialysis Unit. The 
concentrated RBP was stored at — 80° C under argon. 
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3.9 Couple RBP with CNBr-activated sepharose 4B and pack a RBP-sepharose affinity 
column 
The coupling and packing procedures were the same as described above. In our study, 11 
mg RBP was used to pack an affinity column (1.0 X 2.5 cm). 
4. Purify TTR from subject's plasma (Unless otherwise indicated, procedures were carried 
out under yellow light at 4° C) 
4.1 Method 1: Isolate RBP-bound TTR from human plasma. 
(1) Plasma sample preparation 
A subject's plasma (250 mL) was filtered though a 1/4-inch bed of celite to remove lipid. 
Then the plasma was transferred to 3 sections of dialysis membrane tubing (Spectrum 
Medical, Inc) with MWCO of 6000 to 8000. The plasma was dialyzed against 0.05 M 
phosphate buffer pH 7.4 containing 0.0~ M NaCI. i he dialysis was extended to 16 h and the 
buffer was changed 4 times during this period (1St hour, 2nd hour, 3rd hour, and 15th hour). 
Then the plasma was centrifuged at 10000 X g for 30 min to remove any precipitate. The 
clear supernatant was saved for loading onto the DEAF column. 
(2) Ion exchange chromatography (DEAE column: 2.5 X 22 cm) 
The plasma sample was applied to a 100-mL DEAE column which had been equilibrated 
with 0.05 M phosphate buffer pH 7.4 containing 0.05 M NaCI. After all the plasma was 
pumped onto the column, the column was washed with the starting buffer (about 200 mL) 
until there was no absorbance at 280 nm. Immediately after the wash, elution was carried out 
with a linear gradient (500 mL) of NaCI from 0.05 M to 0.5 M in 0.05 M phosphate buffer, 
pH 7.4. Fractions of 5 mL were collected at a flow rate of 70 mL/h. 100 tubes were 
collected and tested for absorbance of 280 nm, 330 nm, 400 nm and also fluorescence (exc 
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335 nm, ext 460 nm). Fractions containing TTR-RBP complex which had both UV 
absorbance and fluorescence were pooled and saved. For multiple uses, the DEAE column 
was cleaned and regenerated using the following protocol recommended by the 
manufacturer: (1) Wash the column with 2 bed volumes of 0.5 M NaOH and allow it to stand 
for 12 h at room temperature; (2) Wash the column with 2 bed volumes of demineralized 
water; (3) Wash the column with 2 bed volumes of 0.5 M phosphate buffer, pH 
(3) Ammonium sulfate precipitation 
The fraction containing RBP-TTR complex was reduced in volume to 50 mL by using an
Amicon Ultrafiltration Cell with YM-3 filter under nitrogen pressure. The sample was then 
precipitated with 1.5 M ammonium sulfate and 2 M citric acid was used to adjust the pH to 
6.0. The protein solution was allowed to stand overnight. It was then centrifuged at 10000 x 
g for 10 min and the supernatant was saved. 
(4) Hydrophobic interaction chromatography (phenyl-sepharose column: 1.5 x 30 cm) 
The 50 mL clear supernatant from the ammonium sulfate precipitation was applied to a 
53-mL phenyl-sepharose column which had been equilibrated with 10 bed volumes of 0.05 
M citrate buffer pH 6.0 containing 1.5 M ammonium sulfate. Fractions of 10 mL were 
collected at a flow rate of 0.72 mL/min. Immediately after loading the protein sample, 
elution was started with a linear gradient from the starting buffer to 0.03 M phosphate buffer, 
pH 7.0 (600 mL). Fractions were tested for absorbance at 280 nm, 330 nm and 400 nm. 
Fractions containing RBP were pooled, concentrated, and saved at — 80° C. The TTR faction 
was concentrated to about 20 mL using the Amicon Ultrafiltration Cell and then further 
purified with the affinity column (see below). For optimal results, the column was stored in 
20% ethanol at 4° C after each use. 
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(5) Affinity Chromatography 
The TTR fraction from the phenyl-sepharose column was dialyzed against the 0.01 
M PBS buffer pH 7.4 containing 0.5 M NaCI. The dialyzed sample was applied to our RBP- 
Sepharose affinity column (1.0 x 2.5 cm) which has been equilibrated with the dialysis 
buffer. Fractions of 2 mL were collected and the flow rate was adjusted to 1.0 mL/min. 
When the entire sample had been pumped onto the column and followed by 1 mL of starting 
buffer, the flow was stopped for 20 min to ensure the binding of TTR to the gel. The column 
was then washed with 3 bed volumes of starting buffer followed with 3 bed volumes of 0.01 
M PBS (no NaCI). The TTR was eluted with at least 8 bed volumes of deionized water. The 
pure TTR was concentrated by the vacuum dialysis unit until a final volume of 0.5 mL was 
obtained. The 0.5 mL TTR sample was then removed from the membrane tube. The 
membrane was washed with PBS buffer 3 times, 0.5 mL each time. The washings were 
combined with the 0.5 mL TTR to obtain a final TTR sample of 2 mL. The sample was 
saved in a brown vial at -80°C under argon. 
4.2 Method 2: Isolate both free TTR and RBP-bound TTR 
(1) Ammonium sulfate precipitation 
To a 100-mL aliquot of plasma from each subject, 19.8 g of ammonium sulfate was 
slowly added to give a final concentration of 1.5 M. The pH was adjusted to 6.0 by 2 M 
citric acid. The protein solution was allowed to stand overnight. The protein solution was 
then centrifuged at 10000 x g for 10 min and the supernatant was saved. 
(2) Hydrophobic interaction chromatography (phenyl-sepharose column: 2.5 x 33 cm) 
A 100-mL of the clear protein solution obtained from the ammonium sulfate precipitation 
was applied to the phenyl-sepharose column using the procedure described above. The only 
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differences were that a 1500 mL buffer gradient was used in here because of the big column 
size, and 1-mL fractions were collected. Fractions were tested for absorbance at 280 nm, 330 
nm, and 450 nm. Three peaks were isolated by this chromatography. These fractions were 
concentrated and analyzed by diode array spectrophotometer for absorbance spectra and by 
SDS-PAGE for purity. Peak 1 which contained TTR was reduced to 5 mL in volume. 
(3) Affinity chromatography 
S-mL aliquots of the concentrated TTR fraction from the peak 1 were each purified 
by affinity chromatography using the procedure described above. The purity of the TTR 
fractions was analyzed by SDS-PAGE. The pooled pure TTR fractions were concentrated by 
the Vacuum Dialysis Unit to a final volume of 2 mL. 
5. SDS-PAGE and immunoblotting 
We performed SDS-PAGE analysis of protein fractions using the NuPage pre-cast 12% 
Bis-Tris gels with appropriate buffers. A XCell SureLock Mini-Cell, NuPage Bis-Tris gel 
(10 wells), NuPage MOPS SDS Running Buffer, NuPage LDS Sample Buffer, and NuPage 
Antioxidant were purchased from Invitrogen (Invitrogen Corporation, Carlsbad, CA, USA). 
Gels were stained using Brilliant Blue G Concentration from Sigma. Immunoblotting was 
done using a BA83 Pure Nitrocellulose Transfer and Immobilization membrane (Schleicher& 
Schuell, Inc., Keene, NH, USA). The Mini Trans-Blot Electrophoretic Transfer Cell and 
Tris/Glycine Transfer Buffer were obtained from Bio-Rad. A Power PAC 200 power supply 
was generously loaned by Dr. Manju Reddy, Department of Food Science and Human 
Nutrition. Perfect Protein AP Western Blot Kits was obtained from Novagen (CN 
Biosciences, Inc, Madison, WI, USA). Prealbumin (N-19, sc-8105) and Bovine anti-goat Ig 
G (sc-2351) were obtained from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, 
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USA). Rabbit Anti-Human Retinol-Binding Protein (RBP) and Alkaline Phosphatase-
Conjugated Goat Anti-Rabbit Immunoglobins were purchased from DAKO (DAKO 
Corporation, Carpinteria, CA, USA). BCIP/NBT Phosphatase Substrate was obtained from 
KPL (KPL, Inc, Gaithersburg, MD, USA). Pure human TTR and RBP were purchased from 
Sigma. The protocols used for SDS-PAGE and immunoblotting were kindly provided by Dr. 
T. Michael Redmond, National Eye Institute, Bethesda, MD. Please see appendix. 
6. Protein concentration 
The protein concentration in the crude and purified samples was measured by the 
Bradford Method. Bradford reagent was purchased from Sigma. 10-µ1 protein samples were 
pipetted onto a 96-well microplate. 10 µl of deionized water was used as a blank. Then 120 
µl of Bradford reagent and 80 µl of deionized water were added to each well. The plate was 
then placed on a shaker for 30 min at room temperature to ensure that sample anc~ reagent 
were well mixed. Then absorbance at 595 nm was measured using an ELX 808 Automated 
Microplate Reader (Bio-Tek Instruments, INC, Winoosk, Vermont, USA). The samples 
were assayed in duplicate or triplicate. This protocol was applied to protein solutions with 
concentration between 50 to 500 mg/mL. Bovine serum albumin was used to prepare a 
standard curve and measured by the same protocol. 
7. Lutein extraction from purified TTR 
The 2-mL TTR solution was mixed with 2 mL of ethanol (0.01 %BHT) in a glass tube to 
precipitate proteins. The mixture was vortexed for 30 sec followed by the addition of 4 mL 
of chloroform (0.01 %BHT). The mixture was partitioned in a separation funnel and the 
chloroform layer was saved. This partition step was repeated 4 times and the chloroform 
fractions were combined and dried under vacuum. 4.8 nmol unlabeled lutein in ethanol 
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(0.01 %BHT) was then added as a carrier to provide adequate mass for GCC-IRMS analysis. 
The combined chloroform extract and spiked unlabeled lutein standard were then dried under 
vacuum again. The dried sample was redissolved in SO µl of ethyl ether + 150 µl mobile 
phase A (methanol + 0.1 %ammonium acetate), and 198 µl was injected into the HPLC. 
8. Lutein derivatization 
The HPLC system used in the isolation of the lutein from the TTR extract was comprised 
of the following equipment (Waters, Milford, MA, USA): a 717P1us Autosampler with 
temperature control set to 5 °C, two 510 solvent delivery systems, and a 996 photodiode 
array detector. The system was operated with Millennium 32 Chromatography Manager 
Software. The lutein fraction was collected from a 5-µm C30 250 X 4.6 mm analytical 
column (Carotenoid Column, YMC, Wilmington, NC, USA). Carotenoids were eluted by a 
linear gradient [ l OU:O methanol (0.1 %ammonium acetate) to 0:100 methyl-tert butyl ether• 
(MTBE) over 30 min (1 ml/min)] . Solvents were HPLC grade and the mobile phase was 
filtered (Whatman Nylon Membrane Filter, 0.2 µm, Whatman International Ltd, Maidstone, 
England). Elution of Carotenoids was monitored at 453 nm. The lutein faction was collected, 
dried under vacuum, and redissolved in 50 µl of ethyl ether + 150 µl of methanol (lg/L 
ammonium acetate) and repurified by injecting 195 µl into the HPLC system, using the same 
reversed-phase HPLC conditions. The lutein peak identities were confirmed by comparison 
of photodiode-array spectra with that of a commercial lutein standard extracted from 
marigold flower (Kemin Foods, Des Moines, IA, USA). Purified lutein was dissolved in 
cyclohexane and hydrogenated to prevent thermal degradation during GC separation prior to 
IR:MS analysis. The hydrogenation tubes were filled with argon. 10 mg of 5% palladium-
on-carbon (Alfa Aesar, Ward Hill, MA, USA) catalyst was added to the tubes promptly, 
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followed by 0.5 mL of HPLC-grade cyclohexane and 0.5 mL of glacial acetic acid containing 
0.02 M p-toluenesulfonic acid monohydrate (Aldrich, Milwaukee, WI, USA) and maintained 
under positive hydrogen gas pressure for 30 min. The purified lutein fraction that was 
suspended in 250 µl of cyclohexane was then added. The reaction mixture was maintained 
under positive hydrogen pressure (12 psi) overnight with stirring at 60° C. The mixture was 
washed twice with 2 mL of HPLC-grade water to remove acid and catalyst. The products 
were dried under vacuum and stored under argon at -20° C until analyzed by GCC-IR:MS. 
9. GCC-IRMS analysis 
A 5 890A Hewlett-Packard (Wilmington, DE, USA) gas chromatograph fitted with a 
Fisons/VG Isotech Isochrom Gas Chromatography-Combustion interface to the Fisons/VG 
Isotech (Micromass UK Ltd, Manchester, UK) Optima Isotope Ratio Mass Spectrometer was 
used to measure the stable carbon ratio of the perhydro-~i-carotene derivative of lutein. A 10 
m X 0.25 mm I.D. (0.25 µm thickness) DBTM — 1 (J&W Scientific, Folsom, CA, USA) fused 
silica capillary column with on-column injector was used as carrier gas at a flow rate of 40 
cm/sec. The temperature program was started from 50° C followed by a gradient of 30° 
C/min to 150° C followed by a gradient of 30° C/min to 150° C followed by a gradient of 15° 
C/min to 325 ° C. Then the temperature was held at 325 ° C for 20 min. After injection into 
the GCC-IRMS, perhydro-~-carotene was quantitatively combusted to CO2 and H2O. Water 
was then removed by a chemical trap and CO2 gas was purified by chromatography on a 
Poropak QS column (4 mm I.D. X 2 m) at 60° C before entry into the dual inlet of the isotope 
ratio mass spectrometer. The computer-generated carbon isotope ratio measurements, 
expressed in delta (~) per mil (%o) units, were used to calculate the atom percent 13C in each 
sample according to the following equation 
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(100 X RPDB) x (813C/1000 + 1) 
Atom% 13C  
1 + (RPDB) x (g13C/1000 + 1) [1] 
where R =13G12C. The RPDB represents the 13G12C ratio for the international standard for 
carbon which was obtained from the Pee Dee Belemnite formation in South Carolina with an 
accepted value of RPDB = 0.0112372 ~ 0.000009. The atom percent (AP) value of lutein was 
calculated based on the mass balance equation (Brenna et al, 1994): 
and AP = 100 X F (in %) [3] 
F,,, is the atom fraction of the mixtures (plasma lutein plus spiked unlabeled lutein 
standard). F is the atom fraction of unlabeled. material and F, is 98% for 13C labeled lutein as 
determined by serial dilution analysis of 13C tracers by using GCC-IRMS. Nis the amount 
of the unlabeled material. N,,, is the final amount of the mixture, and n~ is the amount of 
labeled material. F is determined by directly analyzing the isotope fraction of unlabeled 
lutein standard without hydrogenation by using a NA1500 elemental analyzer (EA) (CE 
Elantech, Lakewood, NJ, USA) interfaced to the Optima Isotope Ratio Mass Spectrometer 
(IRMS). 
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CHAPTER 2. RESULTS 
Purification of 13C-lutein tracer 
The carotenoid composition of our purified 13C-lutein tracer is shown in Figure 1. The 
purity of the 13C-lutein was 96.5% with 3.5% zeaxanthin based on peak area determined by 
HPLC. The ultraviolet/visible absorbance spectrum of our biosynthetic 13C-lutein tracer 
measured by using HPLC with photodiode array detection is shown in Figure 2. It is 
identical to the spectrum of commercial lutein standard (Kemin Industries, Des Moines, IA). 
In Figure 3, the electron ionization (70 ev) mass spectrum shows the fragmentation of our 
13c_labeled lutein which has a base peak of m/z 608.4. The molecular mass of unlabeled 
lutein, a C40 carotenoid, is 568.4. This further confirms the identity of our 13C-lutein tracer in 
which all carbon atoms were uniformly labeled with 13C. 'T'he 13C content of the dose w as 
found to be >98%using GCC-IRMS after serial dilution with unlabeled lutein. 
Purification of TTR from subject's plasma 
The protocols used to purify TTR from human plasma are summarized in Table 1. These 
protocols are highly reproducible and give high yields of pure product comparable to those 
obtained with other methods. About 8 mg of RBP-bound TTR was purified from 250 mL of 
plasma by using Method 1 and 4.7 mg of free TTR was purified from 100 mL of plasma by 
using Method 2. Normal levels of TTR and RBP in human plasma average 200 mg/L and 40 
mg/L, respectively. Therefore, 250 mL and 100 mL contain approximately 60 mg and 20 mg 
of TTR, respectively. Among this, RBP-bound TTR is about 25 mg estimated by the 1: 1 
ratio of TTR binding to RBP. Thus the total recovery of TTR purified using Method 1 is 
34%. Free TTR in 100 mL plasma is about 10 mg and the total recovery of TTR purified 
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Table 1. Purification of transthyretin from human plasma. 
Fraction 
Method 1 (250 mL) Method 2 (100 mL) 
Total protein (mg)* Total protein (mg)* 
Plasma 17050 7540 
DEAE column 13 3 
Ammonium sulfate 86 3900 
precipitation 
Phenyl-sepharose column 39 21 
Affinity column 8.3+ 4.7+
* Protein amount was measured by Bradford method. 
~ Pure TTR 
using Method 2 is 47%. These recoveries are comparable to or even higher than those 
obtained with published methods (107, 108). Figure S shows the SDS-PAGE analysis of the 
fractions isolated from the RBP-Affinity column. The samples were submitted to SDS-
PAGE and compared with pure TTR standard purchased from Sigma. Lanes A, B, C, D, and 
E are Coomassie-stained fractions of our TTR purified by affinity chromatography whereas 
lane F is the commercial TTR standard. The position of the TTR bands in lanes A to lane E 
correspond to the monomeric mass of TTR (14 kDa). 
TTR was purified to homogeneity. The identity of TTR isolated from human plasma was 
confirmed by immunoblot. The result is shown in Figure 6. Our purified TTR was highly 
reactive with anti-TTR antibodies which further confirms the identity of our TTR isolated 
from our subjects' plasma. 
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With Method 1, we did not observe visibly yellow color in the TTR fraction during the 
purification procedure. However, when the initial DEAE chromatography step was omitted 
in Method 2, each of the 3 fractions collected from the phenyl-sepharose column (TTR, RBP 
and unidentified 3rd fraction) were visible yellow. Each of the concentrated fractions was 
analyzed by photodiode-array (PDA) spectrophotometer and SDS-PAGE (Figure 7). In 
addition to the protein absorbance at 280 nm, the TTR-containing fraction (peak 1) showed 
absorbance from 400 to 500 nm with the maximum absorbance at 414 nm (Figure 8). Peak 2 
(containing RBP) and Peak 3 also showed absorbance from 380 nm to 550 nm (Figure 8). 
But none of these peaks had a spectrum characteristic of a carotenoid. When the TTR-
containing peak was applied to the RBP-affinity column to obtain further purification, no 
yellow color was observed in the final purified TTR faction. The PDA spectrophotometric 
data supported this observation. There was no absorbance between 400 and 500 nm in the 
final purified TTR fraction (Figure 9). 
A B ~ Q E F 
15o kDa 
10t) kE3a 
?5 kDa 
5C) kL~a 
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9 ~ kC1a 
Figure 5. SDS-PAGE of human TTR isolated with affinity chromatography: (A-E) 
purified TTR, (F) commercial TTR standard. 
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Figure 6. SDS-PAGE gel (left) and immunoblot (right) of human TTR: commercial TTR 
standard (A and C), purified TTR from human plasma (B and D). 
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Figure 7. SDS-PAGE of material isolated with phenyl-sepharose column: Coomassie-
stainedpeak 1 (A), peak 2 (B), peak 3 (C), commercial human RBP 
standard (D), and commercial human TTR standard (E). 
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Figure 8. Absorbance spectra of fractions isolated with phenyl-sepharose column by 
using Method 2. 
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Figure 9. UV/visible absorbance spectrum of TTR purified to homogeneity by using 
RBP-affinity chromatography 
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Extraction of the associated component from the human TTT~ 
The TTR was precipitated with ethanol and extracted with chloroform (0.01 %BHT). 4.8 
nM of unlabeled lutein was added to obtain a visible peak during HPLC isolation and 
sufficient mass to enable GCC-IRMS analysis. The HPLC chromatogram is shown in Figure 
10. The major peak which eluted at 12.253 min is a mixture of 13C-lutein and unlabled 
lutein. The unlabeled lutein was also analyzed by HPLC using the same procedure. The 
HPLC chromatograms of both unlabeled lutein and extract of the subjects' sample spiked 
with unlabeled lutein are similar with regard to the carotenoid profile. 
40 
L
--: s
~: 
~'~"` 
:`4`~~~--1--~--. 
~l~ 
CC 
41 
Derivatization of lutein 
Because lutein is thermally labile, it must be converted to a heat stable form for GCC- 
IRMS analysis. Catalytic hydrogenation of lutein produces the major product perhydro-(3- 
carotene and secondary products (95). The identity of the major product was confirmed by 
GC-MS. The electron ionization (70 eV) mass spectrum shows the fragmentation of 
perhydro-(3-carotene with mass at m/z 558.7 (Figure 10). The incomplete yield of perhydro- 
(3-carotene produced from lutein derivatization suggested a potential for isotopic fractionation 
during the hydrogenation of plasma lutein for GCC-IRMS analysis. The stable carbon 
isotope ratio (expressed as b13 C vs. the international standard, PDB, in permil units, denoted 
as %o) of lutein measured without derivatization by elemental analyzes (EA-IRMS) was 
-30.82 ~ 0.10 %o (mean ~ SD; n= 4); the stable carbon isotope ratio of perhydro-(3-carotene 
product of lutein hydrogenation measured by using GCC-IRMS was -30.97 ~ 0.27 °oo (mean 
~ SD; n= 7). Thus our protocol for derivatization of lutein did not result in carbon isotopic 
fractionation which would preclude accurate determination of 13C enrichment in lutein 
isolated from human TTR. 
GCC-IRMS analysis 
A representative GCC-IRMS plot of hydrogenationed lutein is shown in Figure 11. A 
well-defined perhydro-(3-carotene peak indicated ahighly-purified sample and enables high 
precision measurement of the 13G12C ratio. In our study, the carbon atoms of the perhydro- 
(3-carotene derivative of lutein are combusted to CO2, which is admitted to the mass 
spectrometer. Ion currents at m/z 44 (1X02), 45 (13C0z + IZC1~0160), and 46 (12C'g0 160) 
are continuously monitored using three Faraday cup detectors. To control for instrumental 
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Figure 12. GCC-IRMS plot of derivatization product of lutein. 
effects, the isotope ratio of COZ derived from the analyte is compared with that from a CO2
standard, Pee Dee Belemnite (PDB). Results are expressed in S notation defined as 
Rsample - Rstandard 
b (%o) _ ~ ) X 103
Rstandard 
where R is the 13C/12C ratio. The computer-generated b value is used to calculate the atom 
percent 13C in the analyte, as previously described. The carbon isotope ratios (b 13C) of 
lutein from 3 subj ects' TTR extracts by using Method 1 were -3 0.5 7, -29.17, and -27.3 3, 
respectively. The b 13C for the subject whose TTR was purified by using Method 2 was 
-35.04. These values were not signification difference from the b ~3C of -30.82 %o 
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determined from the unlabeled lutein standard, which indicated that there was no 13C 
enrichment in the TTR extract. 
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CHAPTER 3. DISCUSSION 
In this study, we successfully purified and crystallized 13C-labeled lutein from crude lipid 
extract of 13C-labeled algae. The purity of our 13C-labeled lutein tracer was 96.5% with 3.5% 
zeaxanthin and no ~-carotene. Human subjects were dosed with purified 13C-labeled lutein 
for 3 days and 500 mL of blood of each subject were collected for the TTR isolation. Also, 
in this study, both TTR and RBP were purified in homogeneity from human plasma. A large 
amount of TTR and RBP were purified from liters of outdated human plasma and used as 
ligands for the affinity columns. TTR-sepharose affinity column and RBP-sepharose affinity 
columns were packed in our lab. The affinity columns were used repeatedly during a period 
of 10 months without sign of degradation or loss of binding capacity. With Method 1, 7.6 
mg, 8.0 mg, and 8.3 mg of RBP-bound TTR were purified from 3 subjects' plasma (250 mL), 
respectively. With Method 2, 4.7 mg of free TTR was obtained from I subj ect's plasma (100 
mL). 
Purification of the tracer 
Purified 13C-labeled lutein is not commercially available. Green algae are a good source 
of biosynthetic carotenoids. Green algae grown in aclosed-system using 13CO2 as the sole 
carbon source were used in our previous studies to economically produce 13C-labeled lutein 
for use as a stable tracer (95). In this study, acetone was used initially to extract carotenoids 
from the crude lipid extract of the algae. Hexane, which is a good solvent for carotenoids 
with low toxicity and high volatility, was then used to extract carotenoids and exclude other 
fat soluble materials. A modified solvent partitioning procedure based on a protocol 
established in our lab (95) was used to purify lutein. Since lutein has two hydroxyl groups, it 
is easily partitioned into the methanol phase whereas ~i-carotene remains in the hexane phase. 
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With methanol/hexane partitioning, ~3-carotene and lutein can be separated and then further 
purified by crystallization. Ethyl ether was used after the methanol partitioning because it 
has high volatility and is easy to evaporate to obtain dry products. Hexane is a good solvent 
for (3-carotene but not for lutein. The solubility of (3-carotene and lutein in hexane are 600 
mg/L and 20 mg/L, respectively. Hence it is used during the wash step for additional 
removal of (3-carotene contamination from the lutein products. At least 1 mg of carotenoid is 
necessary for crystallization. Crystallization of lutein can be achieved by dissolving purified 
dried lutein in wane (40° C) methanol and then storing it at -20° C overnight. Using this 
protocol, high purity (> 96%) of 13C-labeled lutein tracer can be obtained with minute 
contamination by zeaxanthin (~3%) and no (3-carotene. 
TTR purification 
TTR occurs in human plasma as a tetramer composzd of apparently identical subunits 
each of 14 kDa molecular weight. Each subunit contains one polypeptide chain with a single 
cysteinyl residue at position 10 (98). RBP forms a stable protein-protein complex with TTR 
in human circulation, with an association constant of the order of 106 to 10~ (99). The 
interaction of RBP with TTR is very sensitive both to ionic strength and to pH (100, 101). 
RBP and TTR do not form a complex at an ionic strength of 2 mM or lower, and RBP-TTR 
affinity decreases rapidly above pH 9 and below pH 5 (101). 
Isolation of TTR and RBP are notably difficult, laborious, and time consuming. A 
number of procedures for the purification of human TTR and RBP have been reported (102). 
Most of the reported purification schemes are similar in that they employ combinations of 
ion-exchange chromatography and gel filtration or affinity chromatography to achieve human 
TTR and RBP purification. In these schemes, TTR and RBP have been isolated from serum 
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or plasma by first isolating the RBP-TTR complex and then dissociating the complex into 
two components. Then more specific chromatography was carried out to obtain the more 
purified form of each protein. Berni et al. (103) reported a new purification method. In their 
procedure, aphenyl-sepharose CL-4B column was employed. This hydrophobic interaction 
chromatography coupled to the ammonium sulfate precipitation is used to dissociate the 
RBP-TTR complex and eliminates the bulk of other plasma proteins. The dissociation of 
RBP-TTR complex may result from the existence of hydrophobic regions in the contact areas 
between the two proteins that compete for the hydrophobic binding sites on the matrix. As 
an alternative explanation, the complex may bind to the matrix with relatively high affinity 
and release RBP at the end of the gradient, when the ionic strength of the eluant is 0.05 and, 
therefore, possibly favorable for the dissociation of the complex. Use of affinity 
chromatography in purification of TTR or RBP has been reported by several researchers 
(104, 105). This procedure is highly reproducible and gives good recoveries of highly 
purified material. In addition, once packed, the affinity column is extremely stable and can 
be used repeatedly over a period of 8 months for more than 50 chromatographies without 
degradation or any signs of decrease in capacity (104). 
In our study, we used a purification procedure provided by Dr. David Ong, Vanderbilt 
University, which consisted ofion-exchange chromatography (DEAE column), hydrophobic 
interaction chromatography (phenyl-sephaose column), and affinity chromatography. Large 
amounts of pure TTR and RBP for preparing affinity columns are not commercially available 
so we needed to isolate pure TTR and RBP from human plasma. We used outdated human 
plasma provided by a local blood bank as our source of human TTR and RBP. After pure 
TTR was obtained by several isolation chromatographies (ion-exchange chromatography, 
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hydrophobic interaction chromatography, and a 2nd ion-exchange chromatography), aTTR-
sepharose column was packed and used to purify RBP. When the desired amount of pure 
RBP was obtained, a RBP-sepharose column was packed. These two affinity columns were 
tested for their performance before use in isolation of TTR from our subjects' samples. The 
SDS-PAGE and immunoblot showed only a single band in both pure TTR and RBP 
fractions. The RBP-affinity column was employed in the purification of our subjects' TTR. 
To purify TTR from our subject's samples, two methods were used. The first is comprised of 
ion-exchange chromatography (DEAF column), hydrophobic interaction chromatography 
(phenyl-sepharose column), and affinity chromatography (RBP-sepharose column). With 
this method, only RBP-bound TTR was isolated from human plasma. The final product 
(pure human TTR) purified by the RBP-affinity column did not have visible color or 
absorbance in the range from 400 to 550 nm a5 analyzed using a PDA spectrophotometer. 
In Method 2, with a smaller initial volume (100 mL) of plasma, we used ammonium 
sulfate precipitation combined with phenyl-sepharose column as the first step. This protocol 
allowed us to isolate both RBP-bound TTR as well as free TTR. A total of 3 peaks were 
eluted and analyzed with the PDA spectrophotometer. Each peak had yellow color but of 
different intensities. The SDS-PAGE analysis showed that peak 1 contained TTR while peak 
2 contained RBP. The PDA spectrophotometric data indicated that components with 
absorbance in the range of 400 nm to 550 nm were present in a113 peaks. However, the 
spectra of these 3 peaks did not show the typical spectra characteristics of carotenoids which 
have three strong absorbance maxima in the region 400 to S00 nm (Figure 7). Protein 
sequence data suggested that the major protein which occurred in all 3 peaks is lipoprotein A 
which is a maj or protein present in HDL. The yellow color disappeared after peak 1 was 
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further purified by affinity chromatography. In the final pure TTR product, no yellow color 
or absorbance between 400 and 550 nm were detected. 
Derivatization of lutein 
The conjugated polyene system of carotenoids is thermally unstable. Therefore, lutein 
must be converted to derivatives that are thermally stable and volatile at approximately 
300° C prior to GCC-IRMS analysis (94). Catalytic hydrogenation of lutein produces a 
major product perhydro-(3-carotene (m/z 558.6) and secondary products. Our protocol for 
hydrogenation for lutein was optimized by increasing the yield of perhydro-(3-carotene. 
Several catalysts were evaluated in our laboratory for their activities and efficiency in the 
reaction of alcohol hydrogenolysis and hydrogenation of lutein to yield perhydro- (3-carotene. 
Palladium was found to be the best catalyst for lutein (95). 
Solvents are also critical in the carotenoid hydrogenation reaction. 'They serve to increase 
the ease of handling, to moderate exothermic reactions, to increase rate and selectivity, and to 
permit hydrogenation of solid material (107). In the case of lutein, solvents that contain 
peroxide should be avoided to prevent possible degradation of the carotenoids (108). Our 
experience indicated that cyclohexane and acetic acid were the best solvent for the 
hydrogenolysis and hydrogenation of lutein (95). 
Since the amount of lutein associated with TTR is expected to be very small, it is 
important to ensure sufficient and reliable yield of the perhydro-(3-carotene from the lutein 
derivatization. Our data indicated that the protocol we used can achieve excellent yield of 
perhydro-(3-carotene during the hydrogenolysis and hydrogenation of lutein, which enabled 
reliable GCC-IRMS analysis of nanomolar quantities of lutein. Our data also showed that 
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our protocol for the lutein derivatization does not result in carbon isotope fractionation, and 
therefore the perhydro-(3-carotene product is well-suited for GCC-IRMS. 
GCC-IRMS analysis 
Recently, GCC-IRMS was applied to investigate carotenoid metabolism in humans. The 
high precision of GCGIRMS coupled with use of aper-labeled tracer enables use of a 
physiological amount of tracer dose and distinguishes the administered carotenoid from 
endogenous carotenoid. Previously, we used the high precision of GCGIRMS to detect 
differences of natural abundance of 13C in lutein isolated from C3 and C4 plant sources (94). 
Based on our current GCC-IRMS data, no 13Glabeled lutein was detected in an extract of 
purified human TTR. In chickens, the extent of saturation of TTR with lutein was estimated 
to be about 50% and the binding stoichiometry was assumed to be a 1:1 molar ratio (68). We 
calculate that even if only a 1:100 molar ratio of lutein to TTR existed, the GCC-IRMS 
would detect enrichment of 13Glutein in our TTR extracts. The absence of 13C-lutein in the 
extract of TTR obtained using our two isolation methods suggests that lutein is not associated 
with TTR in human blood, at least within the detection limits of current technology. Purified 
chicken TTR is a tetramer (molecular weight of 56 kDa) of four identical subunits (each with 
a molecular weight of approximately 13 kDa) and its thus similar to human TTR (108). 
However, chicken TTR is immunologically (108) and electostatically (109) different from 
those of human and rat. The protein sequence and structure study revealed 31 chicken to 
human residue differences. Compared with human TTR chicken TTR shows quite large 
differences in the region know to be involved in binding to retinol-binding protein; it has a 
much shorter helical component than the human protein and some of the monomer-monomer 
interactions are different (110). It is also reported that the N-termini of the TTR subunits are 
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longer and more hydrophobic in chicken than in mammalian TTR (111). Systematic changes 
of protein structure during evolution lead to changes in function. Although the 
concentrations of TTR are similar in chicken and human (68), there are functional differences 
between chicken and human TTR. RBP and TTR forma 1:1 complex in human plasma (73) 
and 2:1 in chicken plasma (112). In humans, carotenoids are transported mainly by 
lipoproteins, which are less abundant in chicken plasma (113). In addition, human thyroxine 
is transported bound to TTR (40%), thyroxine-binding globulin, TBG (50%), and albumin 
(10%). Chicken plasma does not contain TBG. About 80% of chicken thyroxine binds to 
albumin and less than 20% to TTR (114). Hence thyroxine binding to TTR is significantly 
lower in chicken than in human plasma. These differences further suggest that it is likely 
different ligands would associate with chicken TTR and human TTR. 
The component accounting for the yellow color observed in the TTR-containing peak 
isolated from the phenyl-sepharose column in Method 2 showed an absorbance spectrum 
similar to the pterin derivative, 7,8-dihydropterin-6-carboxaldehyde, which was found to be 
associated with TTR in Ernstrom's study (88). Pterin, the 2-amino, 4-hydroxy derivative of 
pteridine was named from its identification in the wings of butterflies. Plants can use pterin, 
p-aminobenzoate (PABA), and glutamate moieties to synthesize folates (115). Folates are 
essential cofactors for one-carbon transfer reactions in all organisms. However, our results 
showed that all 3 peaks isolated by using hydrophobic interaction chromatography were 
associated with yellow components which have similar absorbance spectra. Thus our results 
suggested the possibility of nonspecific association. The 7,8-dihydropterin-6-carboxaldehyde 
(yellow color) is know to be formed by photochemical degradation of biopterin (uncolored) 
under anaerobic conditions (116). In Ernstrom's study (88), they reported this yellow 
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component was highly unstable and rapidly degraded to uncolored compounds when exposed 
to air. That may also explain why we did not observe yellow color in TTR after the final 
purification step using affinity chromatography. This unstable component may have 
degraded during this additional purification step. Alternatively, the yellow pigment may 
have been associated with protein contaminants that were removed during the final 
purification. 
53 
CHAPTER 4. CONCLUSIONS 
Lutein and zeaxanthin are carotenoids present in a wide variety of vegetables and fruits. 
They are found particularly in green leafy vegetables such as spinach, collards, and kale. 
Lutein and zeaxanthin are more polar than many other carotenoids due to the presence of 
hydroxyl groups on the cyclic ring structure. Unlike the provitamin A carotenoids (a-
carotene, ~3-carotene, and cryptoxanthin), they cannot be converted to vitamin A in mammals. 
Mammals are not biochemically capable of biosynthesizing carotenoids. carotenoids present 
in blood and tissues originate from the diet. 
Growing epidemiological and clinical evidence suggests that lutein and zeaxanthin have 
protective effects against some chronic disease, particularly against eye diseases. In order to 
fully understand how lutein may benefit human health, a mechanistic understanding of the 
metabolism of lutein when ingested by humans in physiological arriounts is needed. In this 
study, we used a biosynthetic 13C-lutein tracer and gas chromatography-combustion 
interfaced-isotope ratio mass spectrometry (GCC-IRMS) to investigate whether TTR could 
serve as a selective transport protein for lutein in human plasma and could thereby account 
for the selective accumulation of lutein in the human macula. The sensitivity of GCC-IRMS 
together with use of a stable tracer enabled us to detect a minute amount of lutein if bound to 
our hypothesized transport protein, transthyretin. 
This study was challenging due to the dif~ cult, laborious, and time-consuming isolation 
of 13C-lutein tracer and plasma TTR and RBP in high purity. In this study, we successfully 
purified and crystallized 13C-labeled lutein from crude lipid extract of 13C-labeled algae. The 
purity of our 13C-labeled lutein tracer was 96.5% with 3.5%zeaxanthin and no ~3-carotene. 
Also, in this study, both TTR and RBP were purred in homogeneity from human plasma. 
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TTR-sepharose affinity column and RBP-sepharose affinity column were packed in our lab. 
The affinity columns were used repeatedly during a period of 10 months without any sign of 
degradation or loss of binding capacity. 
We found no 13Glutein enrichment in the pure TTR extract. This result indicated that 
lutein is not associated with TTR (either RBP-bound TTR or free TTR) in human plasma 
after ingestion in physiological amounts. Some hydrophobic compounds with yellow color 
may bind to human TTR in the plasma. However, this association needs to be further proved 
by showing specificity. It might be interesting to attempt to purify TTR directly from serum 
by RBP-affinity chromatography without any prior purification. However, this would 
require a large amount of RBP to pack the affinity column. Given that RBP occurs only in 
small amounts (40 mg/L) in human plasma, the purification work would be very time 
consuming. 
Our study provides new insight into carotenoid-binding protein studies using a stable 
isotope tracer method combined with the high precision of GCC-IRMS. Previous studies in 
carotenoid-binding proteins usually employed exogenous radioactive carotenoids which may 
not be applied in human study. In the study of retinal membrane proteins, XBP were only 
partially purified (64). Co-elution with endogenous carotenoids cannot prove the specific 
association between proteins and carotenoids. Future studies should be conducted to obtain 
highly purified proteins and evidence of their specific association with carotenoids. The 
methods we described above maybe applied in the investigation of either lutein-specific 
plasma transport proteins or retinal membrane-associated binding proteins. 
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APPENDIX 
SDS-PAGE 
1. Prepare running buffer 
NuPage MOPS running buffer 5 0 mL 
Ultrapure water 9 5 0 mL 
Invert to mix. 
Set aside 800 mL + 200 mL. 
2.Prepare sample and Perfect protein standard solutions. 
Sample or standard 30 µL 
Ultrapure water 2.5 µL 
LDS sample buffer12.5 µL 
Mix gently. 
Add reducing agent 5µL 
Mix gently. 
Heat 10 min at 70°. 
Centrifuge briefly (about 1 min) in microcentrifuge. 
Do not place samples on ice. 
3. Prepare the gel. 
Cut open the pouch and remove the NuPage gel. 
Rinse the gel cassette with d. water. *Peel off the tape from the bottom of the 
cassette. 
In one smooth motion, gently pull the comb out of the cassette. 
Use an automatic pipette to rinse the sample wells with running buffer. Invert the gel 
and shake to remove the buffer. Repeat two more times. 
Orient 2 gels in the Mini-cell so that the notched "well" side faces inward toward the 
buffer core. 
If you are running one gel, the plastic buffer dam replaces the second gel cassette. 
Lock into place with the cam. 
*Add 500 µL of NuPage Running Buffer Antioxidant to 200 mL of running buffer. 
Invert to mix. 
Fill the inner buffer chamber with 200 mL of running buffer. 
Fill the outer buffer chamber with 800 mL of running buffer. 
4. Load the gel. 
For 10 wells (1 mm thickness), load 25 µL for samples and 5µL for Perfect Protein 
marker. 
5. Run the gel. 
with the power turned off, plug the black and red leads into the power supply. 
Run at 200 V for ~ 5 5 min. 
Shut off the power. 
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Disconnect electrodes. 
Remove gel. 
TRANSFER 
1. Prepare the transfer buffer. 
Prepare 1 L Tris Glycine buffer according to the directions on the bottle (don't need 
nanopure water). *Don't use Tris Glycine SDS buffer. 
2. Prepare the gel. 
Separate the 3 bonded sides of the gel with the gel knife. (The well side of the gel 
should face up.) 
Carefully remove and discard the top plate allowing the gel to remain on the bottom 
plate. 
Use a razor to cut off the bottom lip of the gel (3 cuts initially). 
Cut the bottom right-hand corner of the gel. 
Flip the gel and wash for 5-10 min in buffer while set up the transfer. 
3. Prepare the membrane and blotting paper. 
*Cut nitrocellulose (Protran for protein) membrane at bottom right edge with scissors. 
Label edge of membrane using Skillcraft pen. 
Need ~ sheets of 3 ream ~ap~r fir 2 gels. 
Use about 700 mL of transfer buffer to soak the pads, paper, and membranes. 
Assemble on the dark surface: 
Scotchbrite pad 
2layers 3 mm paper 
Flip gel (cut edge is now lower left corner.) Combs face straight edge. 
Nitrocellulose membrane (writing faces gel) 
Roll with glass pasteur pipette to remove excess buffer. 
2layers 3 mm paper 
Roll with glass pasteur pipette to remove excess buffer. 
Scotchbrite pad 
Clear surface. 
Clamp (slides) together. 
4. Transfer 
Fill the inner chamber until the gel/membrane sandwich is just covered with 
transfer buffer. Don't fill all the way to the top; this will only generate extra conductivity 
and heat. 
Fill the outer buffer chamber with transfer buffer. 
Load frosted chamber with ice to prevent overheating. 
With the power turned off, plug the black and red leads into the power supply. 
Set power supply at 200 V for 1.5 hours. 
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IMMUNOBLOT 
1. Prepare blocking solution (TIBS, 3%BSA). 
7.5 mL BSA (20% solution) 
42 mL (20X wash solution, TIBS — KPL) 
**Handle membrane with forceps. 
2. Stain membrane with 0.1 % Ponceau S. (in 1 %acetic acid) 
Approximately 5 min on shaker. 
Rinse with d. water. 
Don't let blots dry. 
3. Block 
Rinse membrane with TIBS-3%BSA for 1 h (cover with parafilm). 
Remark membrane to indicate which antibody. Blot with Kimwipe before 
writing with Skillcraft pen. 
4. Add primary antibody. 
Keep antibody on ice. 
Dilute antibody (1:1000 = ~' µL in 5 mL far HIS tag or 1:2~~~C~O 2.5 µL in 5 r.~I_.) in 
TIBS-3%BSA in conical plastic centrifuge tube .with orange cap. Rinse pipette 
tip in solution. 
Use smallest possible tray. Label trays with tape. 
Add 5 mL antibody solution. 
Incubate on shaker (1 h to overnight). 
5. Wash with TIBS (NO BSA). 
Keep membrane writing side up. 
3 washes (5 min each) 
6. Incubate with secondary antibody. 
Dilute antibody (3 µL) 1:10,000 in 30 mL TIBS-3%BSA. 
Add 6µL S-tag (1:5,000 dilution). 
Incubate membrane with antibody for 1 hour on shaker. Cover with parafilm. 
7. Wash 3 times (5 min each) with TIBS (NO BSA). 
8. Visualize. 
Decant TIBS solution. Add BCIP/NBT substrate for alkaline phosphatase 
(brown bottle from freezer). 
